Investor presentation for H2 & FY26 of Qualitek Labs Limited
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Qualitek Labs delivered strong FY26 results with consolidated revenue of Rs 124.5 Cr, achieving its stated Rs 125 Cr target and marking a 77% year-on-year increase from Rs 70.2 Cr in FY25. EBITDA grew 80% to Rs 29.3 Cr with 24% margin, while PAT surged 90% to Rs 14.6 Cr with 12% margin. The company has grown revenue 4x since listing on BSE in January 2024, now with 10 owned labs and 6 PPP labs across India. For FY27, management targets 35-40% revenue growth, EBITDA margin expansion to 25-26%, and PAT margins of 15-17%. Capex of Rs 63 Cr is planned for FY27 including new labs in Gandhidham, Panipat, Bengaluru and new testing capabilities (EMI/EMC, analytical labs).
The presentation confirms strong execution with 4x revenue growth since listing. The margin expansion guidance (EBITDA to 25-26%, PAT to 15-17%) indicates improving operational leverage and could be positive for the stock. The announced capex plans and M&A strategy in Pharma/Food segments provide visible growth pipeline.